NCT00112736 - Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2014

Conditions

Adult Anaplastic AstrocytomaAdult Anaplastic OligodendrogliomaAdult Diffuse AstrocytomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaAdult Mixed GliomaAdult Pilocytic AstrocytomaAdult Pineal Gland AstrocytomaAdult Subependymal Giant Cell AstrocytomaRecurrent Adult Brain Tumor

Interventions

DRUG

erlotinib

Given orally

DRUG

temsirolimus

Given IV

PROCEDURE

therapeutic conventional surgery

Undergo surgical resection

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (8)

15232

University of Pittsburgh, Pittsburgh

20814

National Cancer Institute Neuro-Oncology Branch, Bethesda

53792

University of Wisconsin Hospital and Clinics, Madison

77030

M D Anderson Cancer Center, Houston

78229

University of Texas Health Science Center, San Antonio

90095

University of California Los Angeles, Los Angeles

94115

University of California San Francisco, San Francisco

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH